🚀 VC round data is live in beta, check it out!
Champions Oncology Valuation Multiples
Discover revenue and EBITDA valuation multiples for Champions Oncology and similar public comparables like Research Solutions, Nightingale Health, Senzime, Health Catalyst and more.
Champions Oncology Overview
About Champions Oncology
Champions Oncology Inc is a USA based company which is engaged in the development and sale of state of the art technology solutions and products to personalize the development and use of oncology drugs. The company operates through one segment namely Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). Its POS business assists physicians in developing personalized treatment options for their cancer patients through tumor-specific data obtained from drug panels and related personalized oncology services. The TOS business assists pharmaceutical and biotechnology companies with their drug development process and offers studies or license tumors for use in studies. The company's revenue is majorly derived from research services.
Founded
1985
HQ
Employees
213
Website
Financials (LTM)
EV
$82M
Champions Oncology Financials
Champions Oncology reported last 12-month revenue of $57M and EBITDA of $7M.
In the same LTM period, Champions Oncology generated $29M in gross profit, $7M in EBITDA, and $5M in net income.
Revenue (LTM)
Champions Oncology P&L
In the most recent fiscal year, Champions Oncology reported revenue of $57M and EBITDA of $7M.
Champions Oncology expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $57M | XXX | $57M | XXX | XXX | XXX |
| Gross Profit | $29M | XXX | $29M | XXX | XXX | XXX |
| Gross Margin | 50% | XXX | 50% | XXX | XXX | XXX |
| EBITDA | $7M | XXX | $7M | XXX | XXX | XXX |
| EBITDA Margin | 13% | XXX | 13% | XXX | XXX | XXX |
| EBIT Margin | 8% | XXX | 9% | XXX | XXX | XXX |
| Net Profit | $5M | XXX | $5M | XXX | XXX | XXX |
| Net Margin | 8% | XXX | 8% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Champions Oncology Stock Performance
Champions Oncology has current market cap of $84M, and enterprise value of $82M.
Market Cap Evolution
Champions Oncology's stock price is $6.03.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $82M | $84M | -0.7% | XXX | XXX | XXX | $0.34 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialChampions Oncology Valuation Multiples
Champions Oncology trades at 1.4x EV/Revenue multiple, and 11.2x EV/EBITDA.
EV / Revenue (LTM)
Champions Oncology Financial Valuation Multiples
As of April 18, 2026, Champions Oncology has market cap of $84M and EV of $82M.
Equity research analysts estimate Champions Oncology's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Champions Oncology has a P/E ratio of 17.8x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $84M | XXX | $84M | XXX | XXX | XXX |
| EV (current) | $82M | XXX | $82M | XXX | XXX | XXX |
| EV/Revenue | 1.4x | XXX | 1.4x | XXX | XXX | XXX |
| EV/EBITDA | 11.2x | XXX | 11.2x | XXX | XXX | XXX |
| EV/EBIT | 17.9x | XXX | 16.8x | XXX | XXX | XXX |
| EV/Gross Profit | 2.9x | XXX | 2.9x | XXX | XXX | XXX |
| P/E | 17.8x | XXX | 17.8x | XXX | XXX | XXX |
| EV/FCF | — | XXX | 11.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Champions Oncology Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Champions Oncology Margins & Growth Rates
Champions Oncology's revenue in the last fiscal year grew by 4%.
Champions Oncology's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.1M for the same period.
Champions Oncology Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | — | XXX | 4% | XXX | XXX | XXX |
| EBITDA Margin | 13% | XXX | 13% | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | 146% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.3M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | 13% | XXX | 13% | XXX | XXX | XXX |
| G&A Expenses to Revenue | 16% | XXX | 16% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 12% | XXX | 12% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 42% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Champions Oncology Public Comps
See public comps and valuation multiples for other Contract Research & Manufacturing and Health Data & Analytics comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Champions Oncology | XXX | XXX | XXX | XXX | XXX | XXX |
| Research Solutions | XXX | XXX | XXX | XXX | XXX | XXX |
| Nightingale Health | XXX | XXX | XXX | XXX | XXX | XXX |
| Senzime | XXX | XXX | XXX | XXX | XXX | XXX |
| Health Catalyst | XXX | XXX | XXX | XXX | XXX | XXX |
| Revium Recovery | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Champions Oncology M&A Activity
Champions Oncology acquired XXX companies to date.
Last acquisition by Champions Oncology was on XXXXXXXX, XXXXX. Champions Oncology acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Champions Oncology
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialChampions Oncology Investment Activity
Champions Oncology invested in XXX companies to date.
Champions Oncology made its latest investment on XXXXXXXX, XXXXX. Champions Oncology invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Champions Oncology
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Champions Oncology
| When was Champions Oncology founded? | Champions Oncology was founded in 1985. |
| Where is Champions Oncology headquartered? | Champions Oncology is headquartered in United States. |
| How many employees does Champions Oncology have? | As of today, Champions Oncology has over 213 employees. |
| Who is the CEO of Champions Oncology? | Champions Oncology's CEO is Robert Brainin. |
| Is Champions Oncology publicly listed? | Yes, Champions Oncology is a public company listed on Nasdaq. |
| What is the stock symbol of Champions Oncology? | Champions Oncology trades under CSBR ticker. |
| When did Champions Oncology go public? | Champions Oncology went public in 1994. |
| Who are competitors of Champions Oncology? | Champions Oncology main competitors are Research Solutions, Nightingale Health, Senzime, Health Catalyst. |
| What is the current market cap of Champions Oncology? | Champions Oncology's current market cap is $84M. |
| What is the current revenue of Champions Oncology? | Champions Oncology's last 12 months revenue is $57M. |
| What is the current EV/Revenue multiple of Champions Oncology? | Current revenue multiple of Champions Oncology is 1.4x. |
| Is Champions Oncology profitable? | Yes, Champions Oncology is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Champions Oncology? | Champions Oncology's last 12 months EBITDA is $7M. |
| What is Champions Oncology's EBITDA margin? | Champions Oncology's last 12 months EBITDA margin is 13%. |
| What is the current EV/EBITDA multiple of Champions Oncology? | Current EBITDA multiple of Champions Oncology is 11.2x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.